(June 13, 2018, 1:31 PM EDT) -- ALEXANDRIA, Va. — A claimed form of synthetically interfering ribonucleic acid (RNAi) molecules is not entitled to patent protection, Alnylam Pharmaceuticals Inc. asserts in a June 11 petition for post-grant review by the Patent Trial and Appeal Board (Alnylam Pharmaceuticals Inc. v. Silence Therapeutics GmbH, No. PGR2018-00067, PTAB)....